Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen

Celcuity (NASDAQ:CELC) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

CELC has been the topic of several other reports. Stifel Nicolaus raised their price objective on Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wolfe Research reissued an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $122.00 target price on shares of Celcuity in a research report on Thursday, March 26th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $109.88.

Celcuity Trading Up 6.6%

NASDAQ:CELC opened at $121.03 on Friday. The business’s 50-day moving average is $113.30 and its two-hundred day moving average is $99.84. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. Celcuity has a 12 month low of $9.51 and a 12 month high of $128.28. The firm has a market capitalization of $5.85 billion, a PE ratio of -31.93 and a beta of 0.41.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.09. Research analysts predict that Celcuity will post -3.97 earnings per share for the current fiscal year.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of Celcuity stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This trade represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the transaction, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently bought and sold shares of CELC. Creative Planning acquired a new position in Celcuity in the second quarter worth about $177,000. Rhumbline Advisers grew its stake in Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares in the last quarter. XTX Topco Ltd acquired a new position in Celcuity in the second quarter worth about $169,000. Quantinno Capital Management LP grew its stake in Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after purchasing an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co grew its stake in Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock worth $1,097,000 after purchasing an additional 60,849 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.